nodes	percent_of_prediction	percent_of_DWPC	metapath
Nabumetone—CYP1A2—Carmustine—lymphatic system cancer	0.0612	1	CbGbCtD
Nabumetone—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.0026	0.00277	CcSEcCtD
Nabumetone—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00259	0.00276	CcSEcCtD
Nabumetone—Stomatitis—Carmustine—lymphatic system cancer	0.00259	0.00276	CcSEcCtD
Nabumetone—Rash—Mechlorethamine—lymphatic system cancer	0.00258	0.00275	CcSEcCtD
Nabumetone—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00258	0.00274	CcSEcCtD
Nabumetone—Weight decreased—Vincristine—lymphatic system cancer	0.00257	0.00274	CcSEcCtD
Nabumetone—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00256	0.00273	CcSEcCtD
Nabumetone—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00255	0.00272	CcSEcCtD
Nabumetone—Pneumonia—Vincristine—lymphatic system cancer	0.00255	0.00272	CcSEcCtD
Nabumetone—Depression—Vincristine—lymphatic system cancer	0.00253	0.0027	CcSEcCtD
Nabumetone—Anorexia—Fludarabine—lymphatic system cancer	0.00253	0.00269	CcSEcCtD
Nabumetone—Weight increased—Mitoxantrone—lymphatic system cancer	0.00252	0.00269	CcSEcCtD
Nabumetone—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00251	0.00267	CcSEcCtD
Nabumetone—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.0025	0.00266	CcSEcCtD
Nabumetone—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.0025	0.00266	CcSEcCtD
Nabumetone—Myocardial infarction—Vincristine—lymphatic system cancer	0.00249	0.00265	CcSEcCtD
Nabumetone—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00249	0.00265	CcSEcCtD
Nabumetone—Feeling abnormal—Teniposide—lymphatic system cancer	0.00248	0.00265	CcSEcCtD
Nabumetone—Stomatitis—Vincristine—lymphatic system cancer	0.00247	0.00263	CcSEcCtD
Nabumetone—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00246	0.00263	CcSEcCtD
Nabumetone—Chills—Bleomycin—lymphatic system cancer	0.00245	0.00261	CcSEcCtD
Nabumetone—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00244	0.00259	CcSEcCtD
Nabumetone—Renal failure—Mitoxantrone—lymphatic system cancer	0.00243	0.00259	CcSEcCtD
Nabumetone—Nausea—Mechlorethamine—lymphatic system cancer	0.00243	0.00259	CcSEcCtD
Nabumetone—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00242	0.00258	CcSEcCtD
Nabumetone—Alopecia—Bleomycin—lymphatic system cancer	0.00242	0.00257	CcSEcCtD
Nabumetone—Jaundice—Mitoxantrone—lymphatic system cancer	0.00241	0.00257	CcSEcCtD
Nabumetone—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00241	0.00257	CcSEcCtD
Nabumetone—Haemoglobin—Carmustine—lymphatic system cancer	0.0024	0.00255	CcSEcCtD
Nabumetone—Urticaria—Teniposide—lymphatic system cancer	0.00239	0.00255	CcSEcCtD
Nabumetone—Glossitis—Methotrexate—lymphatic system cancer	0.00239	0.00254	CcSEcCtD
Nabumetone—Haemorrhage—Carmustine—lymphatic system cancer	0.00239	0.00254	CcSEcCtD
Nabumetone—Abdominal pain—Teniposide—lymphatic system cancer	0.00238	0.00254	CcSEcCtD
Nabumetone—Body temperature increased—Teniposide—lymphatic system cancer	0.00238	0.00254	CcSEcCtD
Nabumetone—Paraesthesia—Fludarabine—lymphatic system cancer	0.00238	0.00253	CcSEcCtD
Nabumetone—Hyperuricaemia—Methotrexate—lymphatic system cancer	0.00237	0.00253	CcSEcCtD
Nabumetone—Dyspnoea—Fludarabine—lymphatic system cancer	0.00236	0.00252	CcSEcCtD
Nabumetone—Haematuria—Mitoxantrone—lymphatic system cancer	0.00236	0.00251	CcSEcCtD
Nabumetone—Dyspepsia—Fludarabine—lymphatic system cancer	0.00233	0.00248	CcSEcCtD
Nabumetone—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00231	0.00246	CcSEcCtD
Nabumetone—Decreased appetite—Fludarabine—lymphatic system cancer	0.0023	0.00245	CcSEcCtD
Nabumetone—Visual impairment—Carmustine—lymphatic system cancer	0.0023	0.00245	CcSEcCtD
Nabumetone—Fatigue—Fludarabine—lymphatic system cancer	0.00228	0.00243	CcSEcCtD
Nabumetone—Constipation—Fludarabine—lymphatic system cancer	0.00227	0.00241	CcSEcCtD
Nabumetone—Vasculitis—Methotrexate—lymphatic system cancer	0.00226	0.0024	CcSEcCtD
Nabumetone—Blood uric acid increased—Methotrexate—lymphatic system cancer	0.00224	0.00239	CcSEcCtD
Nabumetone—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00223	0.00238	CcSEcCtD
Nabumetone—Hypersensitivity—Teniposide—lymphatic system cancer	0.00222	0.00237	CcSEcCtD
Nabumetone—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00222	0.00236	CcSEcCtD
Nabumetone—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00221	0.00235	CcSEcCtD
Nabumetone—Anaemia—Bleomycin—lymphatic system cancer	0.0022	0.00234	CcSEcCtD
Nabumetone—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00218	0.00233	CcSEcCtD
Nabumetone—Asthenia—Teniposide—lymphatic system cancer	0.00216	0.0023	CcSEcCtD
Nabumetone—Melaena—Methotrexate—lymphatic system cancer	0.00215	0.00229	CcSEcCtD
Nabumetone—Malaise—Bleomycin—lymphatic system cancer	0.00215	0.00229	CcSEcCtD
Nabumetone—Pruritus—Teniposide—lymphatic system cancer	0.00213	0.00227	CcSEcCtD
Nabumetone—Arrhythmia—Carmustine—lymphatic system cancer	0.00213	0.00227	CcSEcCtD
Nabumetone—Leukopenia—Bleomycin—lymphatic system cancer	0.00213	0.00227	CcSEcCtD
Nabumetone—Alopecia—Carmustine—lymphatic system cancer	0.00211	0.00225	CcSEcCtD
Nabumetone—Body temperature increased—Fludarabine—lymphatic system cancer	0.00209	0.00223	CcSEcCtD
Nabumetone—Cough—Bleomycin—lymphatic system cancer	0.00208	0.00221	CcSEcCtD
Nabumetone—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00207	0.0022	CcSEcCtD
Nabumetone—Diarrhoea—Teniposide—lymphatic system cancer	0.00206	0.0022	CcSEcCtD
Nabumetone—Alopecia—Vincristine—lymphatic system cancer	0.00201	0.00214	CcSEcCtD
Nabumetone—Discomfort—Bleomycin—lymphatic system cancer	0.002	0.00213	CcSEcCtD
Nabumetone—Chills—Mitoxantrone—lymphatic system cancer	0.00199	0.00212	CcSEcCtD
Nabumetone—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00198	0.00211	CcSEcCtD
Nabumetone—Alopecia—Mitoxantrone—lymphatic system cancer	0.00196	0.00209	CcSEcCtD
Nabumetone—Confusional state—Bleomycin—lymphatic system cancer	0.00196	0.00209	CcSEcCtD
Nabumetone—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00195	0.00208	CcSEcCtD
Nabumetone—Tremor—Carmustine—lymphatic system cancer	0.00195	0.00207	CcSEcCtD
Nabumetone—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00194	0.00207	CcSEcCtD
Nabumetone—Oedema—Bleomycin—lymphatic system cancer	0.00194	0.00207	CcSEcCtD
Nabumetone—Anaemia—Carmustine—lymphatic system cancer	0.00192	0.00205	CcSEcCtD
Nabumetone—Vomiting—Teniposide—lymphatic system cancer	0.00192	0.00204	CcSEcCtD
Nabumetone—Agitation—Carmustine—lymphatic system cancer	0.00191	0.00203	CcSEcCtD
Nabumetone—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.0019	0.00203	CcSEcCtD
Nabumetone—Asthenia—Fludarabine—lymphatic system cancer	0.0019	0.00202	CcSEcCtD
Nabumetone—Rash—Teniposide—lymphatic system cancer	0.0019	0.00202	CcSEcCtD
Nabumetone—Dermatitis—Teniposide—lymphatic system cancer	0.0019	0.00202	CcSEcCtD
Nabumetone—Headache—Teniposide—lymphatic system cancer	0.00189	0.00201	CcSEcCtD
Nabumetone—Pruritus—Fludarabine—lymphatic system cancer	0.00187	0.002	CcSEcCtD
Nabumetone—Leukopenia—Carmustine—lymphatic system cancer	0.00186	0.00198	CcSEcCtD
Nabumetone—Anorexia—Bleomycin—lymphatic system cancer	0.00185	0.00197	CcSEcCtD
Nabumetone—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.00185	0.00197	CcSEcCtD
Nabumetone—Anaemia—Vincristine—lymphatic system cancer	0.00183	0.00195	CcSEcCtD
Nabumetone—Agitation—Vincristine—lymphatic system cancer	0.00182	0.00194	CcSEcCtD
Nabumetone—Photosensitivity—Methotrexate—lymphatic system cancer	0.00182	0.00194	CcSEcCtD
Nabumetone—Diarrhoea—Fludarabine—lymphatic system cancer	0.00181	0.00193	CcSEcCtD
Nabumetone—Hypertension—Carmustine—lymphatic system cancer	0.00179	0.00191	CcSEcCtD
Nabumetone—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00179	0.00191	CcSEcCtD
Nabumetone—Nausea—Teniposide—lymphatic system cancer	0.00179	0.00191	CcSEcCtD
Nabumetone—Anaemia—Mitoxantrone—lymphatic system cancer	0.00178	0.0019	CcSEcCtD
Nabumetone—Vertigo—Vincristine—lymphatic system cancer	0.00178	0.0019	CcSEcCtD
Nabumetone—Hepatic failure—Methotrexate—lymphatic system cancer	0.00178	0.00189	CcSEcCtD
Nabumetone—Leukopenia—Vincristine—lymphatic system cancer	0.00178	0.00189	CcSEcCtD
Nabumetone—Anxiety—Carmustine—lymphatic system cancer	0.00176	0.00188	CcSEcCtD
Nabumetone—Paraesthesia—Bleomycin—lymphatic system cancer	0.00174	0.00186	CcSEcCtD
Nabumetone—Malaise—Mitoxantrone—lymphatic system cancer	0.00174	0.00186	CcSEcCtD
Nabumetone—Dyspnoea—Bleomycin—lymphatic system cancer	0.00173	0.00184	CcSEcCtD
Nabumetone—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00173	0.00184	CcSEcCtD
Nabumetone—Hypertension—Vincristine—lymphatic system cancer	0.00171	0.00182	CcSEcCtD
Nabumetone—Confusional state—Carmustine—lymphatic system cancer	0.00171	0.00182	CcSEcCtD
Nabumetone—Oedema—Carmustine—lymphatic system cancer	0.0017	0.00181	CcSEcCtD
Nabumetone—Decreased appetite—Bleomycin—lymphatic system cancer	0.00169	0.0018	CcSEcCtD
Nabumetone—Cough—Mitoxantrone—lymphatic system cancer	0.00169	0.0018	CcSEcCtD
Nabumetone—Vomiting—Fludarabine—lymphatic system cancer	0.00168	0.00179	CcSEcCtD
Nabumetone—Rash—Fludarabine—lymphatic system cancer	0.00167	0.00178	CcSEcCtD
Nabumetone—Dermatitis—Fludarabine—lymphatic system cancer	0.00167	0.00178	CcSEcCtD
Nabumetone—Hypertension—Mitoxantrone—lymphatic system cancer	0.00167	0.00178	CcSEcCtD
Nabumetone—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00166	0.00177	CcSEcCtD
Nabumetone—Headache—Fludarabine—lymphatic system cancer	0.00166	0.00177	CcSEcCtD
Nabumetone—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00165	0.00176	CcSEcCtD
Nabumetone—Anxiety—Mitoxantrone—lymphatic system cancer	0.00164	0.00175	CcSEcCtD
Nabumetone—Discomfort—Mitoxantrone—lymphatic system cancer	0.00162	0.00173	CcSEcCtD
Nabumetone—Oedema—Vincristine—lymphatic system cancer	0.00162	0.00172	CcSEcCtD
Nabumetone—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00162	0.00172	CcSEcCtD
Nabumetone—Anorexia—Carmustine—lymphatic system cancer	0.00162	0.00172	CcSEcCtD
Nabumetone—Feeling abnormal—Bleomycin—lymphatic system cancer	0.0016	0.0017	CcSEcCtD
Nabumetone—Confusional state—Mitoxantrone—lymphatic system cancer	0.00159	0.00169	CcSEcCtD
Nabumetone—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00158	0.00169	CcSEcCtD
Nabumetone—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00158	0.00168	CcSEcCtD
Nabumetone—Oedema—Mitoxantrone—lymphatic system cancer	0.00158	0.00168	CcSEcCtD
Nabumetone—Nausea—Fludarabine—lymphatic system cancer	0.00157	0.00168	CcSEcCtD
Nabumetone—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00156	0.00167	CcSEcCtD
Nabumetone—Shock—Mitoxantrone—lymphatic system cancer	0.00155	0.00165	CcSEcCtD
Nabumetone—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00154	0.00164	CcSEcCtD
Nabumetone—Urticaria—Bleomycin—lymphatic system cancer	0.00154	0.00164	CcSEcCtD
Nabumetone—Anorexia—Vincristine—lymphatic system cancer	0.00154	0.00164	CcSEcCtD
Nabumetone—Body temperature increased—Bleomycin—lymphatic system cancer	0.00154	0.00164	CcSEcCtD
Nabumetone—Insomnia—Carmustine—lymphatic system cancer	0.00153	0.00163	CcSEcCtD
Nabumetone—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00152	0.00162	CcSEcCtD
Nabumetone—Paraesthesia—Carmustine—lymphatic system cancer	0.00152	0.00162	CcSEcCtD
Nabumetone—Dyspnoea—Carmustine—lymphatic system cancer	0.00151	0.00161	CcSEcCtD
Nabumetone—Somnolence—Carmustine—lymphatic system cancer	0.00151	0.00161	CcSEcCtD
Nabumetone—Anorexia—Mitoxantrone—lymphatic system cancer	0.0015	0.0016	CcSEcCtD
Nabumetone—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00148	0.00157	CcSEcCtD
Nabumetone—Decreased appetite—Carmustine—lymphatic system cancer	0.00147	0.00157	CcSEcCtD
Nabumetone—Insomnia—Vincristine—lymphatic system cancer	0.00146	0.00156	CcSEcCtD
Nabumetone—Paraesthesia—Vincristine—lymphatic system cancer	0.00145	0.00155	CcSEcCtD
Nabumetone—Constipation—Carmustine—lymphatic system cancer	0.00145	0.00154	CcSEcCtD
Nabumetone—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00144	0.00153	CcSEcCtD
Nabumetone—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00143	0.00152	CcSEcCtD
Nabumetone—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00142	0.00151	CcSEcCtD
Nabumetone—Decreased appetite—Vincristine—lymphatic system cancer	0.00141	0.0015	CcSEcCtD
Nabumetone—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00141	0.0015	CcSEcCtD
Nabumetone—Somnolence—Mitoxantrone—lymphatic system cancer	0.0014	0.00149	CcSEcCtD
Nabumetone—Feeling abnormal—Carmustine—lymphatic system cancer	0.0014	0.00149	CcSEcCtD
Nabumetone—Fatigue—Vincristine—lymphatic system cancer	0.0014	0.00149	CcSEcCtD
Nabumetone—Asthenia—Bleomycin—lymphatic system cancer	0.00139	0.00148	CcSEcCtD
Nabumetone—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00139	0.00148	CcSEcCtD
Nabumetone—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00139	0.00148	CcSEcCtD
Nabumetone—Constipation—Vincristine—lymphatic system cancer	0.00138	0.00147	CcSEcCtD
Nabumetone—Asthma—Methotrexate—lymphatic system cancer	0.00138	0.00147	CcSEcCtD
Nabumetone—Pruritus—Bleomycin—lymphatic system cancer	0.00137	0.00146	CcSEcCtD
Nabumetone—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00137	0.00146	CcSEcCtD
Nabumetone—Fatigue—Mitoxantrone—lymphatic system cancer	0.00136	0.00145	CcSEcCtD
Nabumetone—Pancreatitis—Methotrexate—lymphatic system cancer	0.00135	0.00144	CcSEcCtD
Nabumetone—Constipation—Mitoxantrone—lymphatic system cancer	0.00135	0.00144	CcSEcCtD
Nabumetone—Abdominal pain—Carmustine—lymphatic system cancer	0.00134	0.00143	CcSEcCtD
Nabumetone—Body temperature increased—Carmustine—lymphatic system cancer	0.00134	0.00143	CcSEcCtD
Nabumetone—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00132	0.00141	CcSEcCtD
Nabumetone—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.0013	0.00138	CcSEcCtD
Nabumetone—Dysuria—Methotrexate—lymphatic system cancer	0.00129	0.00138	CcSEcCtD
Nabumetone—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00129	0.00137	CcSEcCtD
Nabumetone—Abdominal pain—Vincristine—lymphatic system cancer	0.00128	0.00136	CcSEcCtD
Nabumetone—Body temperature increased—Vincristine—lymphatic system cancer	0.00128	0.00136	CcSEcCtD
Nabumetone—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00127	0.00135	CcSEcCtD
Nabumetone—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00126	0.00134	CcSEcCtD
Nabumetone—Urticaria—Mitoxantrone—lymphatic system cancer	0.00125	0.00133	CcSEcCtD
Nabumetone—Hypersensitivity—Carmustine—lymphatic system cancer	0.00125	0.00133	CcSEcCtD
Nabumetone—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00125	0.00133	CcSEcCtD
Nabumetone—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00125	0.00133	CcSEcCtD
Nabumetone—Pneumonia—Methotrexate—lymphatic system cancer	0.00124	0.00132	CcSEcCtD
Nabumetone—Vomiting—Bleomycin—lymphatic system cancer	0.00123	0.00132	CcSEcCtD
Nabumetone—Depression—Methotrexate—lymphatic system cancer	0.00123	0.00131	CcSEcCtD
Nabumetone—Rash—Bleomycin—lymphatic system cancer	0.00122	0.0013	CcSEcCtD
Nabumetone—Dermatitis—Bleomycin—lymphatic system cancer	0.00122	0.0013	CcSEcCtD
Nabumetone—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00122	0.0013	CcSEcCtD
Nabumetone—Asthenia—Carmustine—lymphatic system cancer	0.00122	0.0013	CcSEcCtD
Nabumetone—Renal failure—Methotrexate—lymphatic system cancer	0.00121	0.00129	CcSEcCtD
Nabumetone—Stomatitis—Methotrexate—lymphatic system cancer	0.0012	0.00128	CcSEcCtD
Nabumetone—Hypersensitivity—Vincristine—lymphatic system cancer	0.00119	0.00127	CcSEcCtD
Nabumetone—Haematuria—Methotrexate—lymphatic system cancer	0.00117	0.00125	CcSEcCtD
Nabumetone—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00116	0.00124	CcSEcCtD
Nabumetone—Asthenia—Vincristine—lymphatic system cancer	0.00116	0.00124	CcSEcCtD
Nabumetone—Diarrhoea—Carmustine—lymphatic system cancer	0.00116	0.00124	CcSEcCtD
Nabumetone—Nausea—Bleomycin—lymphatic system cancer	0.00115	0.00123	CcSEcCtD
Nabumetone—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00115	0.00122	CcSEcCtD
Nabumetone—Asthenia—Mitoxantrone—lymphatic system cancer	0.00113	0.0012	CcSEcCtD
Nabumetone—Dizziness—Carmustine—lymphatic system cancer	0.00112	0.00119	CcSEcCtD
Nabumetone—Haemoglobin—Methotrexate—lymphatic system cancer	0.00111	0.00118	CcSEcCtD
Nabumetone—Diarrhoea—Vincristine—lymphatic system cancer	0.00111	0.00118	CcSEcCtD
Nabumetone—Haemorrhage—Methotrexate—lymphatic system cancer	0.00111	0.00118	CcSEcCtD
Nabumetone—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00108	0.00115	CcSEcCtD
Nabumetone—Vomiting—Carmustine—lymphatic system cancer	0.00108	0.00115	CcSEcCtD
Nabumetone—Dizziness—Vincristine—lymphatic system cancer	0.00107	0.00114	CcSEcCtD
Nabumetone—Rash—Carmustine—lymphatic system cancer	0.00107	0.00114	CcSEcCtD
Nabumetone—Dermatitis—Carmustine—lymphatic system cancer	0.00107	0.00114	CcSEcCtD
Nabumetone—Visual impairment—Methotrexate—lymphatic system cancer	0.00107	0.00113	CcSEcCtD
Nabumetone—Headache—Carmustine—lymphatic system cancer	0.00106	0.00113	CcSEcCtD
Nabumetone—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00105	0.00111	CcSEcCtD
Nabumetone—Tinnitus—Methotrexate—lymphatic system cancer	0.00103	0.0011	CcSEcCtD
Nabumetone—Vomiting—Vincristine—lymphatic system cancer	0.00103	0.0011	CcSEcCtD
Nabumetone—Rash—Vincristine—lymphatic system cancer	0.00102	0.00109	CcSEcCtD
Nabumetone—Dermatitis—Vincristine—lymphatic system cancer	0.00102	0.00109	CcSEcCtD
Nabumetone—Headache—Vincristine—lymphatic system cancer	0.00101	0.00108	CcSEcCtD
Nabumetone—Nausea—Carmustine—lymphatic system cancer	0.00101	0.00107	CcSEcCtD
Nabumetone—Vomiting—Mitoxantrone—lymphatic system cancer	0.001	0.00107	CcSEcCtD
Nabumetone—Rash—Mitoxantrone—lymphatic system cancer	0.000994	0.00106	CcSEcCtD
Nabumetone—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000993	0.00106	CcSEcCtD
Nabumetone—Chills—Methotrexate—lymphatic system cancer	0.000992	0.00106	CcSEcCtD
Nabumetone—Headache—Mitoxantrone—lymphatic system cancer	0.000987	0.00105	CcSEcCtD
Nabumetone—Alopecia—Methotrexate—lymphatic system cancer	0.000977	0.00104	CcSEcCtD
Nabumetone—Nausea—Vincristine—lymphatic system cancer	0.000961	0.00102	CcSEcCtD
Nabumetone—Nausea—Mitoxantrone—lymphatic system cancer	0.000936	0.000997	CcSEcCtD
Nabumetone—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000893	0.000951	CcSEcCtD
Nabumetone—Anaemia—Methotrexate—lymphatic system cancer	0.000889	0.000947	CcSEcCtD
Nabumetone—Malaise—Methotrexate—lymphatic system cancer	0.000868	0.000924	CcSEcCtD
Nabumetone—Vertigo—Methotrexate—lymphatic system cancer	0.000864	0.000921	CcSEcCtD
Nabumetone—Leukopenia—Methotrexate—lymphatic system cancer	0.000861	0.000917	CcSEcCtD
Nabumetone—Cough—Methotrexate—lymphatic system cancer	0.00084	0.000894	CcSEcCtD
Nabumetone—Discomfort—Methotrexate—lymphatic system cancer	0.000809	0.000862	CcSEcCtD
Nabumetone—Confusional state—Methotrexate—lymphatic system cancer	0.000792	0.000843	CcSEcCtD
Nabumetone—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000785	0.000836	CcSEcCtD
Nabumetone—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000769	0.000819	CcSEcCtD
Nabumetone—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000759	0.000809	CcSEcCtD
Nabumetone—Anorexia—Methotrexate—lymphatic system cancer	0.000749	0.000797	CcSEcCtD
Nabumetone—Insomnia—Methotrexate—lymphatic system cancer	0.00071	0.000757	CcSEcCtD
Nabumetone—Paraesthesia—Methotrexate—lymphatic system cancer	0.000705	0.000751	CcSEcCtD
Nabumetone—Dyspnoea—Methotrexate—lymphatic system cancer	0.0007	0.000746	CcSEcCtD
Nabumetone—Somnolence—Methotrexate—lymphatic system cancer	0.000698	0.000744	CcSEcCtD
Nabumetone—Dyspepsia—Methotrexate—lymphatic system cancer	0.000691	0.000736	CcSEcCtD
Nabumetone—Decreased appetite—Methotrexate—lymphatic system cancer	0.000683	0.000727	CcSEcCtD
Nabumetone—Fatigue—Methotrexate—lymphatic system cancer	0.000677	0.000721	CcSEcCtD
Nabumetone—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000647	0.000689	CcSEcCtD
Nabumetone—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000642	0.000684	CcSEcCtD
Nabumetone—Urticaria—Methotrexate—lymphatic system cancer	0.000624	0.000664	CcSEcCtD
Nabumetone—Abdominal pain—Methotrexate—lymphatic system cancer	0.000621	0.000661	CcSEcCtD
Nabumetone—Body temperature increased—Methotrexate—lymphatic system cancer	0.000621	0.000661	CcSEcCtD
Nabumetone—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000579	0.000616	CcSEcCtD
Nabumetone—Asthenia—Methotrexate—lymphatic system cancer	0.000563	0.0006	CcSEcCtD
Nabumetone—Pruritus—Methotrexate—lymphatic system cancer	0.000556	0.000592	CcSEcCtD
Nabumetone—Diarrhoea—Methotrexate—lymphatic system cancer	0.000537	0.000572	CcSEcCtD
Nabumetone—Dizziness—Methotrexate—lymphatic system cancer	0.000519	0.000553	CcSEcCtD
Nabumetone—Vomiting—Methotrexate—lymphatic system cancer	0.000499	0.000532	CcSEcCtD
Nabumetone—Rash—Methotrexate—lymphatic system cancer	0.000495	0.000527	CcSEcCtD
Nabumetone—Dermatitis—Methotrexate—lymphatic system cancer	0.000495	0.000527	CcSEcCtD
Nabumetone—Headache—Methotrexate—lymphatic system cancer	0.000492	0.000524	CcSEcCtD
Nabumetone—Nausea—Methotrexate—lymphatic system cancer	0.000466	0.000497	CcSEcCtD
